Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Topoisomerase I poison-triggered immune gene activation is markedly reduced in human small-cell lung cancers by impairment of the cGAS/STING pathway

6 Jul 2022

Abstract excerpt

BACKGROUND: Current immunotherapy strategies have contrasting clinical results in human lung cancer patients as small-cell lung cancers (SCLC) often show features of immunological cold tumours. Topoisomerase 1 (TOP1) poisons are effective antitumor drugs with good efficacy against lung cancers. METHODS: We used molecular, genetic and bioinformatic approaches to determine the mechanism of micronuclei formation...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer therapeutics and mechanisms
Share to interferon and immune responses
Share to Lung Cancer Research Studies

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 35794238
DOI: 10.1038/s41416-022-01894-4

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Topoisomerase I poison-triggered immune gene activation is markedly reduced in human small-cell lung cancers by impairment of the cGAS/STING pathwayPMID 35794238Read ↗

Targeting DNA Damage Response Promotes Antitumor Immunity through STING-Mediated T-cell Activation in Small Cell Lung CancerSemantic proximity Read ↗

DNA-PK inhibition sustains the antitumor innate immune response in small cell lung cancerSemantic proximity Read ↗

Mutant RB1 enhances therapeutic efficacy of PARPis in lung adenocarcinoma by triggering the cGAS/STING pathwaySemantic proximity Read ↗

Targeting the loss of cGAS / STING signaling in cancerSemantic proximity Read ↗

PARP1 inhibitors trigger innate immunity via PARP1 trapping-induced DNA damage responseSemantic proximity Read ↗

Anti-cancer immune responses to DNA damage response inhibitors: Molecular mechanisms and progress toward clinical translationSemantic proximity Read ↗

Targeting the DNA Damage Response Machinery for Lung Cancer TreatmentSemantic proximity Read ↗

Targeting a non-oncogene addiction to the ATR/CHK1 axis for the treatment of small cell lung cancerSemantic proximity Read ↗

Triple kill: DDR inhibitors, radiotherapy and immunotherapy leave cancer cells with no escapeSemantic proximity Read ↗

Pharmacological rescue of tumor intrinsic STING expression and immune response in LKB1-mutant lung cancer via the IAP-JAK regulatory axisSemantic proximity Read ↗

APE1 promotes radiation resistance against radiation-induced pyroptosis by inhibiting the STING pathway in lung adenocarcinomaSemantic proximity Read ↗

PARP Inhibitors in Small-Cell Lung Cancer: Rational Combinations to Improve ResponsesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.